Latest in News & Research

Comorbidity Burden Higher in Generalized Pustular Psoriasis

Most prevalent conditions in GPP were hypertension, psoriatic arthritis, type 2 diabetes, hyperlipidemia

By Physician’s Briefing Staff | | October 19, 2022

Online Symptom Checkers Often Not Accurate for ID'ing Skin Rashes

Even when correct in diagnosis, broad differentials and low specificity of results contribute to diagnostic uncertainty

By Physician’s Briefing Staff | | October 18, 2022

COVID-19 Mainly Mild, Moderate in Eczema Patients Receiving Tralokinumab

76 of 77 patients with COVID-19 were unvaccinated; no new safety signals reported after COVID-19 vaccination

By Dermsquared Editorial Team | | October 12, 2022

Instruments ID'd for Measuring Eczema Control, Itch Intensity

Consensus reached for Recap of Atopic Eczema and Atopic Dermatitis Control Tool for measuring eczema control

By Dermsquared Editorial Team | | October 12, 2022

Lenabasum Studied for Refractory Cutaneous Dermatomyositis

Results of phase 2 study suggest clinical benefit and favorable safety profile, warranting further study of lenabasum for DM

By Physician's Briefing Staff | | October 11, 2022

Treatment Sequence Studied for Advanced BRAF-Mutant Melanoma

Two-year overall survival higher for those initiating treatment with combo nivolumab/ipilimumab versus dual BRAF/MEK inhibition

By Physician’s Briefing Staff | | October 06, 2022

High Sunburn Frequency Through Life Linked to Melanoma, cSCC Risk

Stable high and high-to-low trajectories had increased risks compared with stable low trajectory

By Dermsquared Editorial Team | | October 05, 2022

More Eczema Patients Achieve Itch-Free State With Ruxolitinib

Difference in itch numerical rating scale 0/1 was significant on day 2 and persisted through week 8

By Dermsquared Editorial Team | | October 05, 2022

IV Immune Globulin Bests Placebo for Dermatomyositis

More adults receiving IVIG versus placebo had Total Improvement Score of at least 20 at 16 weeks

By Physician's Briefing Staff | | October 05, 2022

Apremilast May Offer Cardiometabolic Benefit in Psoriasis Patients

5 to 6 percent decrease seen in subcutaneous and visceral adiposity at week 16 of treatment, which was maintained at 52 weeks

By Physician’s Briefing Staff | | October 04, 2022

FDA Approves Dupixent for Prurigo Nodularis

This priority review-based approval makes Dupixent the first treatment for the inflammatory skin condition

By Physician’s Briefing Staff | | September 30, 2022

Is Long-Term Tapinarof Cream Safe, Effective for Psoriasis?

For up to one year, 40.9 percent of patients achieved complete disease clearance with a four-month remittive effect; no new safety signals seen

By Dermsquared Editorial Team | | September 28, 2022

Sentinel Lymph Node Biopsy Status Predicts Melanoma Survival

SLN positivity significantly associated with lower five-year disease-specific survival among patients with clinical stage IIB/C cutaneous melanoma

By Dermsquared Editorial Team | | September 28, 2022

Inflammatory Bowel Disease, Psoriasis May Be Causally Related

Genetic predisposition to psoriasis not linked to total IBD, but is associated with Crohn disease

By Physician's Briefing Staff | | September 22, 2022

Several Factors Significantly Tied to Atopic Dermatitis Disease Burden

Strongest associations seen for disease severity and time spent managing symptoms

By Physician’s Briefing Staff | | September 22, 2022

Roflumilast Yields Better Results for Chronic Plaque Psoriasis

Two multicenter trials show significantly greater percentage of patients treated with roflumilast versus vehicle had IGA success at week 8

By Dermsquared Editorial Team | | September 21, 2022

Burden of Ambulatory Hidradenitis Suppurativa Visits Up During Summer

51 percent of ambulatory visits for hidradenitis suppurativa occurred during May to August

By Dermsquared Editorial Team | | September 21, 2022

Psoriasis Patients Find Psoriatic Arthritis Screening Worthwhile

Participants report feeling empowered by comprehensive screening

By Physician’s Briefing Staff | | September 20, 2022

Dupilumab Eases Atopic Dermatitis in Children Younger Than 6 Years

Signs and symptoms of atopic dermatitis improved with dupilumab versus placebo in addition to topical corticosteroids

By Physician’s Briefing Staff | | September 19, 2022

Is Efficacy of Itraconazole for Tinea Corporis/Cruris Higher With Greater Dose?

400-mg dose of itraconazole achieves higher cure rate, but cost is 120 percent greater compared with 100-mg dose

By Dermsquared Editorial Team | | September 14, 2022

Few Europeans Use Photoprotection All Year Round

Only 56 percent of Europeans were aware that sun protection is useful when weather is overcast

By Dermsquared Editorial Team | | September 14, 2022

Causal Effect ID'd for IBD With Psoriasis, Psoriatic Arthritis

Crohn disease, but not ulcerative colitis, associated with psoriasis and psoriatic arthritis

By Physician’s Briefing Staff | | September 14, 2022

TikTok 'Slugging' Trend Has People Coating Their Faces With Grease

To slug or not to slug? That's the question for millions of TikTok users, who turn to the social media giant for tips and...

By Alan Mozes (HealthDay News) | | September 13, 2022

24 of 1292

Headline from the Week of October 19 - 25, 2026

The Distance Between Habit and Strategy

By Dermsquared Editorial Team | | October 23, 2026

From Poster to Practice: The Control Gap in CIndU

| October 23, 2026